Baillie Gifford Sheng Hong has been heard by the Hong Kong Stock Exchange for its listing application, and the sponsor has received the relevant letter.

SiChuan Baili Tianheng Pharmaceutical (688506.SH) announced that the company is applying to issue Listed in Hong Kong shares and is engaged in related work for listing on the Main Board of the Hong Kong Stock Exchange.

Ryanben CapitalDec 21, 2024 14:00

Bailitianheng has received the filing notice for its listing in Hong Kong, planning to issue no more than 24.271 million shares.

On December 12, 2024, the International Cooperation Department of the China Securities Regulatory Commission issued a notice regarding the overseas issuance and listing filing for SiChuan Baili Tianheng Pharmaceutical Co., Ltd. (Guohe Huan [2024] No. 2272).

Ryanben CapitalDec 13, 2024 13:48

New stock news | Bailitianheng's Hong Kong IPO has been filed with the China Securities Regulatory Commission.

On December 12, the China Securities Regulatory Commission published a notification regarding the Overseas issuance and listing of Sichuan Baili Tianheng Pharmaceutical Co., Ltd., which plans to issue no more than 24.271 million shares of ordinary stock for overseas listing and will list on the Hong Kong Stock Exchange.

Zhitong FinanceDec 12, 2024 20:45

Sichuan Biokin Pharmaceutical Gets Clinical Trial Approval for Tumor Antibody Injection

MT NewswiresSep 23, 2024 16:09

Sichuan Biokin Pharmaceutical Enrolls First Patient in Phase 3 Trial of Anti-Cancer Treatment; Shares Slide 3%

MT NewswiresAug 20, 2024 13:53

Sichuan Biokin Pharmaceutical Submits Hong Kong IPO Application

MT NewswiresJul 11, 2024 16:16